AbbVie Cash Flow Statement
NYSE: ABBVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:01 PM ET · Delayed 15 min
AbbVie free cash flow
In fiscal 2025, AbbVie generated $19.03 billion of operating cash flow and spent $1.21 billion on capital expenditures. That left free cash flow of $17.82 billion, a free-cash-flow margin of 29.1% of revenue. Free cash flow was down 0.1% from the prior year's $17.83 billion.
AbbVie returned $12.64 billion to shareholders: $11.66 billion in dividends and $980.0 million in share repurchases, equal to 71% of free cash flow. Free cash flow covered dividend payments 1.5 times.
Summary generated from market data by MetaCap's automated system. Methodology
AbbVie cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 4.23B | 4.29B | 4.87B | 11.85B | 11.55B | 4.62B | 7.88B | 5.69B | 5.31B | 5.95B |
| Net Income growth (YoY) | -1.24% | -12.05% | -58.86% | +2.56% | +149.87% | -41.36% | +38.60% | +7.12% | -10.82% | +15.73% |
| Depreciation & Amortization | 762.00M | 764.00M | 752.00M | 778.00M | 803.00M | 666.00M | 464.00M | 471.00M | 425.00M | 425.00M |
| Stock-Based Compensation | 955.00M | 911.00M | 747.00M | 671.00M | 692.00M | 753.00M | 430.00M | 421.00M | 365.00M | 353.00M |
| Change in Working Capital | -1.60B | 426.00M | 3.30B | -636.00M | 59.00M | 679.00M | -433.00M | -283.00M | 9.00M | -1.69B |
| Operating Cash Flow | 19.03B | 18.81B | 22.84B | 24.94B | 22.78B | 17.59B | 13.32B | 13.43B | 9.96B | 7.04B |
| Capital Expenditures | -1.21B | -974.00M | -777.00M | -695.00M | -787.00M | -798.00M | -552.00M | -638.00M | -529.00M | -479.00M |
| Investing Cash Flow | -6.64B | -20.82B | -2.01B | -623.00M | -2.34B | -37.56B | 596.00M | -1.01B | -274.00M | -6.07B |
| Dividends Paid | -11.66B | -11.03B | -10.54B | -10.04B | -9.26B | -7.72B | -6.37B | -5.58B | -4.11B | -3.72B |
| Share Repurchases | -980.00M | -1.71B | -1.97B | -1.49B | -934.00M | -978.00M | -629.00M | -12.01B | -1.41B | -6.03B |
| Debt Issued | 3.99B | 16.96B | — | 2.00B | 1.00B | 3.00B | 31.48B | 5.96B | 0 | 11.63B |
| Debt Repaid | -6.80B | -9.61B | -4.15B | -14.43B | -9.41B | -5.68B | -1.54B | -6.04B | -25.00M | -6.01B |
| Financing Cash Flow | -12.72B | -5.21B | -17.22B | -24.80B | -19.04B | -11.50B | 18.71B | -14.40B | -5.51B | -3.93B |
| Net Change in Cash | -295.00M | -7.29B | 3.61B | -545.00M | 1.30B | -31.48B | 32.63B | -2.01B | 4.20B | -3.30B |
| Free Cash Flow | 17.82B | 17.83B | 22.06B | 24.25B | 21.99B | 16.79B | 12.77B | 12.79B | 9.43B | 6.56B |
This table shows 10 annual periods of AbbVie's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ABBV's reporting calendar. What is a cash flow statement?